Formerly available as Librium and Osimertinib Mesylate

• Generic Name: chlordiazepoxide
• Dosage Forms: n.a.
• Other Brand Names: Formerly available as Librium, Librium, Libritabs, Poxi, Mitran

Relief of agitation and tremor and prevention or symptomatic relief of delirium tremens and hallucinations associated with acute alcohol withdrawal.

Management of anxiety disorders and short-term relief of symptoms of anxiety.

Management of moderate to severe anxiety (in fixed-combination with amitriptyline hydrochloride) in patients with moderate to severe depression.

Preoperatively to relieve anxiety.

Has been used in fixed combination with clidinium bromide as an adjunct in the treatment of peptic ulcer disease, functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis. Fixed combination is classified by FDA as possibly effective for these indications.

Has limited usefulness in the treatment of peptic ulcer disease because of the advent of more effective therapies for this condition.

Therapeutic benefits achieved with the combination preparation in the management of functional disturbances of GI motility may be attributed to the anxiolytic and/or sedative properties of chlordiazepoxide.

Although the fixed combination has been used in the treatment of acute enterocolitis, antimuscarinic-containing preparations should be used with extreme caution in patients with diarrhea or ulcerative colitis.

• Generic Name: osimertinib
• Dosage Forms: n.a.
• Other Brand Names: Tagrisso

First-line treatment of metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations (as detected by an FDA-approved diagnostic test).

Treatment of metastatic NSCLC in patients with EGFR T790M mutation (as detected by an FDA-approved diagnostic test) who have experienced disease progression during or after EGFR tyrosine kinase inhibitor therapy.

Designated an orphan drug by FDA for treatment of EGFR mutation-positive NSCLC.